Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811164 | 0.98 | IL23R (0.41) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811123 | 0.96 | IL23R (0.39) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811146 | 0.96 | NPY4R (0.38) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811179 | 0.95 | IL23R (0.41) | IL23RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30811165 | 0.95 | IL23R (0.39) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811144 | 0.93 | IL23R (0.37) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811143 | 0.93 | NPY4R (0.36) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811150 | 0.93 | SIRT5 (0.39) | IL23RFNTAFNTBPGGT1BNPY4R | |
| SCHEMBL30811134 | 0.92 | SIRT5 (0.40) | IL23RFNTAFNTBPGGT1BOPRM1 | |
| SCHEMBL31520401 | 0.92 | NPY4R (0.39) | FNTAFNTBPGGT1BNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | disclosed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | IL23R 2482/4885FNTA 1407/4885FNTB 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.